Head-To-Head Survey: Eupraxia Pharmaceuticals (EPRX) versus Its Peers

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is one of 1,021 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Eupraxia Pharmaceuticals to related companies based on the strength of its dividends, profitability, analyst recommendations, risk, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Eupraxia Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	0	0	0	1	4.00
Eupraxia Pharmaceuticals Competitors	6872	19548	46054	997	2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 67.54%. Given Eupraxia Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Eupraxia Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	-$28.22 million	-2.61
Eupraxia Pharmaceuticals Competitors	$1.66 billion	$152.52 million	-4.37

Eupraxia Pharmaceuticals’ competitors have higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Eupraxia Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-255.59%	-85.34%
Eupraxia Pharmaceuticals Competitors	-2,898.46%	-304.88%	-31.81%

Insider & Institutional Ownership

44.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Eupraxia Pharmaceuticals competitors beat Eupraxia Pharmaceuticals on 7 of the 12 factors compared.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.